Skip to content
Bexion Pharmaceuticals Logo Bexion Pharmaceuticals Logo Bexion Pharmaceuticals Logo
  • Investors
  • Platform
  • Pipeline
  • Clinical Trials
  • Resources
    • Case Studies
  • About Bexion
    • Leadership
    • Key Milestones
    • Media & Press
    • Careers
  • Contact
Resourcesneptuneweb2019-10-15T14:14:54-04:00

Resources

Posters

Outcomes of High-Grade Glioma Patients in a Phase 1 Trial of BXQ-350, Cancer-selective SapC-DOPS Nanovesicles
> View

First-in-human, First-in-Class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas
> View

Abstracts

First-in-human, First-in-class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas.
> View


Absence of Indicators of Hypercoagulability and Anti-phospholipid Syndrome in BXQ-350 First in Human Study.
> View


Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles.
> View

Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice.
> View


Safety and Pharmacokinetics of BXQ-350 in a Phase 1a and 1b Trial of Solid Tumors and High-grade Glioma.
> View


High-Grade Glioma outcomes in the Phase 1 BXQ-350 trial of cancer-selective SapC-DOPS nanovesicles
> View

632 Russell Street, Covington, KY 41011

FacebookTwitter
  • Privacy Policy
  • Terms of Use
  • Safe Harbor
© Copyright 2019. All Rights Reserved. Bexion Pharmaceuticals